|
1
|
Soon S, Chia WJ, Redekop K and Wee HL: A
cost-effectiveness analysis of aspirin in the primary prevention of
cardiovascular diseases and colorectal cancer. Value Health.
18:A4622015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wilson LF, Green AC, Kendall BJ, Jordan
SJ, Nagle CM, Bain CJ, Neale RE and Whiteman DC: Cancers prevented
in Australia in 2010 through the consumption of aspirin. Aust NZ J
Public Health. 39:414–417. 2015. View Article : Google Scholar
|
|
3
|
Wright JL, Chéry L, Holt S, Lin DW,
Luedeke M, Rinckleb AE, Maier C and Stanford JL: Aspirin and NSAID
use in association with molecular subtypes of prostate cancer
defined by TMPRSS2: ERG fusion status. Prostate Cancer Prostatic
Dis. 19:53–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mikami J, Kurokawa Y, Takahashi T,
Miyazaki Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Mori M
and Doki Y: Antitumor effect of antiplatelet agents in gastric
cancer cells: an in vivo and in vitro study. Gastric Cancer. Oct
20–2015.(Epub ahead of print).
|
|
5
|
Zhang YP, Wan YD, Sun YL, Li J and Zhu RT:
Aspirin might reduce the incidence of pancreatic cancer: a
meta-analysis of observational studies. Sci Rep. 5:154602015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wan L, Dong H, Xu H, Ma J, Zhu Y, Lu Y,
Wang J, Zhang T, Li T, Xie J, et al: Aspirin, lysine, mifepristone
and doxycycline combined can effectively and safely prevent and
treat cancer metastasis: prevent seeds from gemmating on soil.
Oncotarget. 6:35157–35172. 2015.PubMed/NCBI
|
|
7
|
Gonzalez-Gonzalez M, Garcia J, Alcazar JA,
Gutierrez ML, Gonzalez LM, Bengoechea O, Abad MM, Santos-Briz A,
Blanco O, Martin M, Rodriguez A, Fuentes M, Munoz-Bellvis L, Orfao
A and Sayagues JM: Association between the cytogenetic profile of
tumor cells and response to preoperative radiochemotherapy in
locally advanced rectal cancer. Medicine (Baltimore). 93:e1532014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fontana E, Smyth EC, Cunningham D, Rao S,
Watkins D, Allum WH, Thompson J, Waddell T, Peckitt C, Chau I, et
al: Improved survival in resected oesophageal and gastric
adenocarcinomas over a decade: the Royal Marsden experience
2001–2010. Gastric Cancer. Nov 5–2015.(Epub ahead of print).
PubMed/NCBI
|
|
9
|
Gu Q, Zhang J, Hu H, Tan YE, Shi S and
Nian Y: Clinical significance of MiR-137 expression in patients
with gastric cancer after radical gastrectomy. PLos One.
10:e01423772015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sugimura T and Fujimura S: Tumour
production in glandular stomach of rat by
N-methyl-N'-nitro-N-nitrosoguanidine. Nature. 216:943–944. 1967.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thompson J, Epting T, Schwarzkopf G,
Singhofen A, Eades-Perner AM, van Der Putten H and Zimmermann W: A
transgenic mouse line that develops early-onset invasive gastric
carcinoma provides a model for carcinoembryonic antigen-targeted
tumor therapy. Int J Cancer. 86:863–869. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Furukawa H, Iwanaga T, Nakajima T,
Okabayashi K, Nakazato H, Hiratsuka M, Ohta K, Kito T, Yamamura Y
and Goto S: Randomized study with mitomycin C +
5-fluorouracil+cytosine arabinoside (MFC)+5-fluorouracil,
MFC+tegafur and uracil (UFT), and MF+UFT in advanced gastric
cancer: interinstitutional differences in a multicenter study in
Japan. J Surg Oncol. 60:59–64. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Logan RF, Grainge MJ, Shepherd VC,
Armitage NC and Muir KR: ukCAP Trial Group: Aspirin and folic acid
for the prevention of recurrent colorectal adenomas.
Gastroenterology. 134:29–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Osborn VW, Chen SC, Weiner J, Schwartz D
and Schreiber D: Impact of aspirin on clinical outcomes for African
American men with prostate cancer undergoing radiation. Tumori.
102:65–70. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang WK, Tu HT and See LC: Aspirin use on
incidence and mortality of gastrointestinal cancers: current state
of epidemiological evidence. Curr Pharm Des. 21:5108–5115. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Di Francesco L, López Contreras LA, Sacco
A and Patrignani P: New insights into the mechanism of action of
aspirin in the prevention of colorectal neoplasia. Curr Pharm Des.
21:5116–5126. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kraus S, Sion D and Arber N: Can we select
patients for colorectal cancer prevention with aspirin? Curr Pharm
Des. 21:5127–5134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kastrati I, Litosh VA, Zhao S, Alvarez M,
Thatcher GR and Frasor J: A novel aspirin prodrug inhibits NFκB
activity and breast cancer stem cell properties. BMC Cancer.
15:8452015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheng GZ, Zhang W and Wang LH: Regulation
of cancer cell survival, migration, and invasion by Twist: AKT2
comes to interplay. Cancer Res. 68:957–960. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qin Y, Tang B, Hu CJ, Xiao YF, Xie R, Yong
X, Wu YY, Dong H and Yang SM: An hTERT/ZEB1 complex directly
regulates E-cadherin to promote epithelial-to-mesenchymal
transition (EMT) in colorectal cancer. Oncotarget. 7:351–361.
2016.PubMed/NCBI
|
